Events

Virtual AI Summit w/ Kevin Garwood and Peju Oshisanya

Panel Discussion: AI x Policy: Driving Responsible and Scalable Data Governance Best Practice – Looking Ahead at How External Stakeholders and Governmental Regulations Will Influence Data Strategy

  • Multinational companies – transferring and accessing data across borders, given different jurisdictions/laws/regulations
  • Brexit and the future of GDPR
  • European Union/US/China – what’s next in tech policy? How will it change tech investment and innovation? What does it mean for private companies?
  • Data Diversity
Speakers
  • Richard Self - Senior Lecturer in Governance of Advanced and Emerging Technologies, University of Derby
  • Eline Chivot - Senior Policy Analyst, Center for Data Innovation
  • Edwina Dunn - Co-Founder & Board Member, dunnhumby & Centre for Data Ethics & Innovation
  • Peju Oshisanya - Director – Clinical Programme Leader, Benevolent AI
  • Mike Wiley - Application CTO and VP Engineering, F5

Healthcare Track: Data Diversity Effort at BenevolentAI

→ Register here


Peju Oshisanya
AI Ethics, Data Diversity Advocate, Clinical Drug Development Leader at BenevolentAI

Peju is an innovative operational strategy expert with over 15 years wide-ranging experience relating to strategic programme leadership, planning and management of clinical trials with responsibility for global clinical programmes. She has extensive experience in working in early drug discovery and exploratory phases focused on the transition of early stage assets to clinical development. She has held leadership positions in programme management responsible for key clinical programmes and assets within Eli Lilly, Sanofi Aventis, Pfizer and Takeda. In her current role at BenevolentAI, she is responsible for driving the asset strategy to maximise the value of both early and late phase drug development programmes.

Kevin Garwood
Patient Data Manager at BenevolentAI

Kevin is a patient data manager for precision medicine activities at BenevolentAI and is responsible for managing information governance concerns for patient-level data and in identifying and acquiring clinical and –omic data sources that would support our drug discovery programmes. Kevin’s interests include bioethics, intellectual property law and better understanding the value chain that shapes the worth and applicability of health data in the field of precision medicine. Most of his work involves coordinating with stakeholders from very different parts of the company.


More Posts

You Might Also Like

News
BenevolentAI’s platform-derived hypothesis for COVID-19 treatment validated in US NIAID randomised control trial
NIAID trial shows baricitinib in combination with remdesivir reduces the recovery time in patients hospitalised with COVID-19, validating BenevolentAI’s AI-derived hypothesis.
Sep 14, 2020
Blog
Building the next generation of leaders with Circl
BenevolentAI Director of Talent Acquisition and Development, Yasmina Rahiman, explores the power of coaching for leadership development in technology.
Aug 21, 2020
News
Clinical data validates BenevolentAI's AI predicted hypothesis for baricitinib as a potential treatment for COVID-19
Research published in EMBO Molecular Medicine confirms AI predictions for anti-viral and anti-cytokine signalling effects of baricitinib in critically hospitalised COVID-19 patients
Jul 1, 2020
News
COVID-19 and AI: An editorial review in EMBO from Michael B. Schultz, Daniel Vera, David A. Sinclair
David Sinclair and colleagues review our recent publication in the EMBO Molecular Medicine Journal in support of our AI-derived hypothesis for a potential treatment of COVID-19.
Jul 1, 2020
Video
How do we get the next 10 years right? w/ Joanna Shields, CogX
“We need leaders with empathy who care about their fellow citizens and are prepared to work to end injustice and create opportunities for all". Our CEO Joanna Shields opens CogX 2020 sharing inspiration for the next decade.
Jun 8, 2020
Blog
Kindness matters: mental health and wellbeing through COVID-19 and beyond
To conclude Mental Health awareness week, we share some thoughts about the power of kindness and how building a culture of openness will help shape the future of business.
May 27, 2020